AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12809818 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical (Nissen fundoplication)
Number of subjects: 62
Study 12809818 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical (ranitidine 150 mg t.i.d.)
Number of subjects: 62
Study 12809818 — intervention group
Group type: COMPARATOR
Intervention: Control (antacids as needed)
Number of subjects: 62
Study 10807093 — intervention group
Group type: EXPERIMENTAL
Intervention: Crutches set to conventional guidelines
Number of subjects: 20
Study 10807093 — intervention group
Group type: EXPERIMENTAL
Intervention: Crutches set 2.5 cm longer than conventional guidelines
Number of subjects: 20
Study 10807093 — intervention group
Group type: EXPERIMENTAL
Intervention: Crutches set 2.5 cm shorter than conventional guidelines
Number of subjects: 20
Study 9387512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 126
Study 9387512 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 126
Study 1484022 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gm sucralfate four times a day
Number of subjects: 40
Study 1484022 — intervention group
Group type: COMPARATOR
Intervention: 150 mg ranitidine tablet twice daily
Number of subjects: 40
Study 3926614 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide dinitrate in sustained-release form (sustained-release ISDN)
Number of subjects: 32
Study 3926614 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide 5-mononitrate (IS 5-MN)
Number of subjects: 32
Study 3926614 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg buccal nitroglycerin in sustained-release form (NTGB)
Number of subjects: 32
Study 3926614 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 mg oral nitroglycerin in sustained-release form (NTGO)
Number of subjects: 32
Study 29636305 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) at 30% of maximal inspiratory pressure (MIP) for 6 weeks
Number of subjects: 25
Study 29636305 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 25
Study 29636305 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (5% of MIP) for 6 weeks
Number of subjects: 25
Study 27821107 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture with distal-proximal point association (Neiguan (PC6) and Zhongwan (CV12))
Number of subjects: 240
Study 27821107 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture with distal-proximal point association (Zusanli (ST36) and CV12)
Number of subjects: 240
Study 27821107 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture with local distribution point association (Shangwan (CV13) and CV12)
Number of subjects: 240
Study 27821107 — intervention group
Group type: COMPARATOR
Intervention: Standard antiemetic only
Number of subjects: 240
Study 27821107 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture treatments
Number of subjects: 240
Study 25070320 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1000 IU/d)
Number of subjects: 1787
Study 25070320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1787
Study 22480187 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate insulin therapy (MIT) with glucose target 120 to 140 mg/dl
Number of subjects: 112
Study 22480187 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT) with glucose target 180 to 200 mg/dl
Number of subjects: 112
Study 20678878 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day plus ASA 75 to 100 mg/day
Number of subjects: 851
Study 20678878 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ASA 75 to 100 mg/day
Number of subjects: 851
Study 17511748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 50
Study 17511748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15663583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bishop score
Number of subjects: 266
Study 15663583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length
Number of subjects: 266
Study 12534429 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier social users of alcohol (n=100)
Number of subjects: 200
Study 12534429 — intervention group
Group type: COMPARATOR
Intervention: Lighter social users of alcohol and non‐users (n=100)
Number of subjects: 200
Study 10370642 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 8
Study 10370642 — intervention group
Group type: COMPARATOR
Intervention: NOx levels
Number of subjects: 8
Study 8777101 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 30 micrograms kg‐1
Number of subjects: 60
Study 8777101 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 0.2 mg kg‐1
Number of subjects: 60
Study 8777101 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 0.1 mg kg‐1
Number of subjects: 60
Study 8777101 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60
Study 2051002 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine sulfate 400 mg per day
Number of subjects: 31
Study 2051002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 6881428 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solutions (ORS) containing 90 mmol/liter of sodium
Number of subjects: 93
Study 6881428 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solutions (ORS) containing 50 mmol/liter of sodium
Number of subjects: 93
Study 6881428 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient management (Control)
Number of subjects: 93
Study 30075736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT)
Number of subjects: 300
Study 30075736 — intervention group
Group type: EXPERIMENTAL
Intervention: RapidArc
Number of subjects: 300
Study 30075736 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography/computed tomography (PET/CT) with F‐18 fluorodeoxyglucose (FDG)
Number of subjects: 300
Study 30075736 — intervention group
Group type: EXPERIMENTAL
Intervention: Comet assay‐guided IMRT
Number of subjects: 300
Study 30075736 — intervention group
Group type: EXPERIMENTAL
Intervention: Comet assay‐guided RapidArc
Number of subjects: 300
Study 30075736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m2 weekly for five courses
Number of subjects: 300
Study 30075736 — intervention group
Group type: EXPERIMENTAL
Intervention: Two to four cycles of TP (Taxol 135 mg/m2, D1, and DDP 75 mg/m2, D1‐3) sequential chemotherapy
Number of subjects: 300
Study 26740259 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 664
Study 26740259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 664
Study 24904748 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy combined with spinal manipulation
Number of subjects: 184
Study 24904748 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy alone
Number of subjects: 184
Study 22402803 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower blood pressure goal (mean arterial pressure ≤92 mmHg)
Number of subjects: 949
Study 22402803 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (remaining patients)
Number of subjects: 949
Study 22402803 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial phase (125I-iothalamate-measured GFR)
Number of subjects: 949
Study 22402803 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of proteinuria at baseline
Number of subjects: 949
Study 20384499 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom assessment using the Memorial Symptom Assessment Scale-Short Form (MSAS-SF)
Number of subjects: 212
Study 18480682 — intervention group
Group type: EXPERIMENTAL
Intervention: Peony‐Glycyrrhiza Decoction (PGD) 45 g/d
Number of subjects: 20
Study 18480682 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (BMT) 5 mg/d
Number of subjects: 20
Study 18480682 — intervention group
Group type: EXPERIMENTAL
Intervention: Peony‐Glycyrrhiza Decoction (PGD)
Number of subjects: 20
Study 16316784 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse steroid therapy
Number of subjects: 0
Study 16316784 — intervention group
Group type: COMPARATOR
Intervention: Low dose steroid treatment
Number of subjects: 0
Study 16316784 — intervention group
Group type: COMPARATOR
Intervention: No steroid treatment
Number of subjects: 0
Study 16316784 — intervention group
Group type: EXPERIMENTAL
Intervention: CD14-independent LPS-binding and activation
Number of subjects: 0
Study 14627912 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended daclizumab induction, tacrolimus, and mycophenolate mofetil (MMF)
Number of subjects: 57
Study 14627912 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free protocol
Number of subjects: 57
Study 14627912 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free protocol with modified dosing
Number of subjects: 57
Study 14627912 — intervention group
Group type: COMPARATOR
Intervention: Historical matched steroid-based control
Number of subjects: 57
Study 10998732 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 10998732 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic treatment, radiotherapy, and radioisotopes
Number of subjects: 0
Study 8795448 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (30 p.p.m. for 15 min)
Number of subjects: 19
Study 8795448 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (80 p.p.m. for 15 min)
Number of subjects: 19
Study 8795448 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged inhalation of nitric oxide (30 p.p.m. for 55 min)
Number of subjects: 19
Study 8795448 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (640 mg orally)
Number of subjects: 19
Study 1538279 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and family support services and pediatric follow‐up during the first 3 years of life
Number of subjects: 985
Study 1538279 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 985
Study 6142254 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination of washed motile fraction of spermatozoa
Number of subjects: 35
Study 6142254 — intervention group
Group type: COMPARATOR
Intervention: Natural intercourse timed by symptothermal methods
Number of subjects: 35
Study 6142254 — intervention group
Group type: COMPARATOR
Intervention: LH-timed intercourse
Number of subjects: 35
Study 30554365 — intervention group
Group type: COMPARATOR
Intervention: Glycerine iodine 10% daily for 7 days
Number of subjects: 37
Study 30554365 — intervention group
Group type: COMPARATOR
Intervention: Eniloconazole 10% emulsified concentrate four times with 2 days interval
Number of subjects: 37
Study 30554365 — intervention group
Group type: EXPERIMENTAL
Intervention: Neem seeds extract (20% cream) daily for 10 days
Number of subjects: 37
Study 30554365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumaq extract (5% cream) daily for 10 days
Number of subjects: 37
Study 31299999 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps functional electrical stimulation (FES) synchronized with walking for 10 minutes, three days a week, in addition to standard rehabilitation.
Number of subjects: 23
Study 31299999 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps neuromuscular electrical stimulation (NMES) (duty cycle of 10s on/10s off) for 10 minutes, three days a week, in addition to standard rehabilitation.
Number of subjects: 23
Study 31299999 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps functional electrical stimulation (FES) synchronized with walking.
Number of subjects: 23
Study 31299999 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps neuromuscular electrical stimulation (NMES).
Number of subjects: 23
Study 28301614 — intervention group
Group type: EXPERIMENTAL
Intervention: HP/TAZ lotion (halobetasol propionate 0.01% and tazarotene 0.045%)
Number of subjects: 212
Study 28301614 — intervention group
Group type: COMPARATOR
Intervention: HP lotion (halobetasol propionate 0.01%)
Number of subjects: 212
Study 28301614 — intervention group
Group type: COMPARATOR
Intervention: TAZ (tazarotene 0.045%)
Number of subjects: 212
Study 28301614 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 212
Study 28301614 — intervention group
Group type: EXPERIMENTAL
Intervention: HP/TAZ lotion
Number of subjects: 212
Study 25297660 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-led titration
Number of subjects: 552
Study 25297660 — intervention group
Group type: COMPARATOR
Intervention: Physician-led titration
Number of subjects: 552
Study 25297660 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 552
Study 23747986 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted informed consent format
Number of subjects: 61
Study 23747986 — intervention group
Group type: COMPARATOR
Intervention: Paper version of informed consent
Number of subjects: 61
Study 20817209 — intervention group
Group type: EXPERIMENTAL
Intervention: Lund technique (n = 10)
Number of subjects: 20
Study 20817209 — intervention group
Group type: COMPARATOR
Intervention: Carbon dioxide insufflation technique (n = 10)
Number of subjects: 20
Study 18654783 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of Gd-DTPA (approximately 0.1 mmol/kg bw)
Number of subjects: 10
Study 18654783 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of Gd-DTPA
Number of subjects: 10
Study 17032158 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy plus treatment as usual (CBT plus TAU)
Number of subjects: 106
Study 17032158 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 106
Study 12937052 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone administration (1993-1994 cohort)
Number of subjects: 0
Study 12937052 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone administration (2001 cohort)
Number of subjects: 0
Study 12937052 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic lung disease in survivors (1993-1994 cohort)
Number of subjects: 0
Study 12937052 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic lung disease in survivors (2001 cohort)
Number of subjects: 0
Study 12937052 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality (1993-1994 cohort)
Number of subjects: 0
Study 12937052 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality (2001 cohort)
Number of subjects: 0
Study 10664926 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution (0.5%, 0.05 mL to each eye) with cimetidine (400 mg)
Number of subjects: 12
Study 10664926 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution (0.5%, 0.05 mL to each eye)
Number of subjects: 12
Study 10664926 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 12
Study 10664926 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (400 mg)
Number of subjects: 12
Study 9287258 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 50 mg daily
Number of subjects: 0
Study 9287258 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release dipyridamole 400 mg daily
Number of subjects: 0
Study 9287258 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ASA 25 mg b.d. and dipyridamole 200 mg b.d.
Number of subjects: 0
Study 9287258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8345978 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin/potassium clavulanate
Number of subjects: 519
Study 8345978 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ceftriaxone
Number of subjects: 519
Study 8345978 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 519
Study 3013567 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral sulbactam/ampicillin
Number of subjects: 60
Study 3013567 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin/gentamicin
Number of subjects: 60
Study 31594205 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular distension followed by physical therapy (Group A)
Number of subjects: 122
Study 31594205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular distension preceded by physical therapy (Group B)
Number of subjects: 122
Study 31594205 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy alone (Group C)
Number of subjects: 122
Study 28326609 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized 1-hr training program in suicide prevention
Number of subjects: 162
Study 28326609 — intervention group
Group type: COMPARATOR
Intervention: Stress and time management skills training program
Number of subjects: 162
Study 27181179 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO (40,000 IU/ml)
Number of subjects: 83
Study 27181179 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% NaCl)
Number of subjects: 83
Study 27181179 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO
Number of subjects: 83
Study 25539560 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative therapy before arthroscopic subacromial decompression
Number of subjects: 68
Study 25539560 — intervention group
Group type: COMPARATOR
Intervention: No conservative therapy before arthroscopic subacromial decompression
Number of subjects: 68
Study 25539560 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative therapy before surgery
Number of subjects: 68
Study 25539560 — intervention group
Group type: COMPARATOR
Intervention: No conservative therapy before surgery
Number of subjects: 68
Study 25539560 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after surgery
Number of subjects: 68
Study 22538137 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial self‐monitoring of blood glucose (pp‐SMBG) at least two times a day and dietary modification based on glucose readings
Number of subjects: 169
Study 22538137 — intervention group
Group type: COMPARATOR
Intervention: Dietary modification based on glucose readings but no mandatory pp‐SMBG
Number of subjects: 169
Study 20392615 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor modulation interventions
Number of subjects: 0
Study 20392615 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 18286187 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue combined with artesunate (MB-AS)
Number of subjects: 180
Study 18286187 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue combined with amodiaquine (MB-AQ)
Number of subjects: 180
Study 18286187 — intervention group
Group type: COMPARATOR
Intervention: Artesunate combined with amodiaquine (AS-AQ)
Number of subjects: 180
Study 15805993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (200 microg twice daily for 1 week)
Number of subjects: 26
Study 15805993 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 microg twice daily for 1 week)
Number of subjects: 26
Study 15805993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone and Budesonide
Number of subjects: 26
Study 13129449 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun-dried raisins (120 g/d)
Number of subjects: 13
Study 13129449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream of tartar (5 g/d)
Number of subjects: 13
Study 10567179 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol (50 microg/d) and norethisterone acetate (2.5 mg/d, orally)
Number of subjects: 169
Study 10567179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 8896141 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for depression prevention, specific details not provided.
Number of subjects: 0
Study 8896141 — intervention group
Group type: COMPARATOR
Intervention: Control group, specific details not provided.
Number of subjects: 0
Study 2061443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 14‐9706 (0.05% cream) applied twice daily for 16 weeks
Number of subjects: 25
Study 2061443 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin (0.05% cream) applied twice daily for 16 weeks
Number of subjects: 25
Study 6166458 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 20
Study 6166458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30786738 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulation-Focused Psychotherapy for Children (RFP-C)
Number of subjects: 3
Study 28839984 — intervention group
Group type: EXPERIMENTAL
Intervention: BC1036
Number of subjects: 289
Study 28839984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 25636235 — intervention group
Group type: EXPERIMENTAL
Intervention: vodka/orange juice (20 g alcohol)
Number of subjects: 24
Study 25636235 — intervention group
Group type: COMPARATOR
Intervention: orange juice only
Number of subjects: 24
Study 24627331 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 12944
Study 24627331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12944
Study 18957387 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 694
Study 18957387 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 694
Study 18957387 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg and Atenolol 50 mg (combination)
Number of subjects: 694
Study 15218694 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (Group 2)
Number of subjects: 60
Study 15218694 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking and Alcohol (Group 3)
Number of subjects: 60
Study 15218694 — intervention group
Group type: COMPARATOR
Intervention: Control (Group 1)
Number of subjects: 60
Study 11742270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (0.25 mg/kg body weight administered twice daily)
Number of subjects: 0
Study 11742270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0
Study 11742270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9408935 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential currents (IFC) applied for 30 minutes per day for 10 days at a beat frequency of 10-25 Hz
Number of subjects: 227